Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $15.00 at Oppenheimer

Capricor Therapeutics (NASDAQ:CAPR) had its target price hoisted by Oppenheimer from $14.00 to $15.00 in a report issued on Tuesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock.

Several other research analysts also recently commented on CAPR. HC Wainwright reissued a buy rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday. Maxim Group restated a buy rating and set a $12.00 price target on shares of Capricor Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $20.00.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $5.05 on Tuesday. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $7.28. The stock’s 50-day simple moving average is $4.37 and its 200 day simple moving average is $5.18. The stock has a market capitalization of $161.49 million, a price-to-earnings ratio of -5.80 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. On average, research analysts forecast that Capricor Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Jump Financial LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $258,000. BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics in the first quarter worth about $40,000. Vanguard Group Inc. increased its holdings in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares during the period. Bank of New York Mellon Corp increased its holdings in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the period. Finally, Rhumbline Advisers bought a new position in Capricor Therapeutics during the 2nd quarter valued at approximately $147,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.